Biotech companies are going public earlier and with more initial public offering dollars, which analysts say may reflect more confidence in new technologies, such as gene therapy. Alnylam Pharmaceuticals CEO John Maraganore said this trend reflects the increasing cost of research and development, and an industry that has matured and "proven itself to be a real, sustainable business."
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.